Natia Esiashvili1, Xiaomin Lu2, Ken Ulin3, Fran Laurie3, Sandy Kessel3, John A Kalapurakal4, Thomas E Merchant5, David S Followill6, Vythialinga Sathiaseelan4, Mary K Schmitter3, Meenakshi Devidas2, Yichen Chen2, Donna A Wall7, Patrick A Brown8, Stephen P Hunger9, Stephan A Grupp9, Michael A Pulsipher10. 1. Emory University Winship Cancer Institute, Atlanta, Georgia. Electronic address: nesiash@emory.edu. 2. Children's Oncology Group Data Center, Biostatistics, University of Florida, Gainesville, Florida. 3. Imaging and Radiation Oncology Rhode Island QA Center, Lincoln, Rhode Island. 4. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois. 5. St Jude Children's Research Hospital, Memphis, Tennessee. 6. Imaging and Radiation Oncology Rhode Island QA Center, Houston, Texas. 7. Manitoba Blood and Marrow Transplant Program, Winnipeg, Manitoba, Canada. 8. Johns Hopkins University Kimmel Cancer Center, Baltimore, Maryland. 9. Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, Philadelphia, Pennsylvania. 10. Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
Abstract
PURPOSE: To examine the relationship between lung radiation dose and survival outcomes in children undergoingtotal body irradiation (TBI)-based hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia on the Children's Oncology Group trial. METHODS AND MATERIALS: TBI (1200 or 1320 cGy given twice daily in 6 or 8 fractions) was used as part of 3 HSCT preparative regimens, allowing institutional flexibility regarding TBI techniques, including lung shielding. Lung doses as reported by each participating institution were calculated for different patient setups, with and without shielding, with a variety of dose calculation techniques. The association between lung dose and transplant-related mortality, relapse-free survival, and overall survival (OS) was examined using the Cox proportional hazards regression model controlling for the following variables: TBI dose rate, TBI fields, patient position during TBI, donor type, and pre-HSCT minimal residual disease level. RESULTS: Of a total of 143 eligible patients, 127 had lung doses available for this analysis. The TBI techniques were heterogeneous. The mean lung dose was reported as 904.5 cGy (standard deviation, ±232.3). Patients treated with lateral fields were more likely to receive lung doses ≥800 cGy (P < .001). The influence of lung dose ≥800 cGy on transplant-related mortality was not significant (hazard ratio [HR], 1.78; P = .21). On univariate analysis, lung dose ≥800 cGy was associated with inferior relapse-free survival (HR, 1.76; P = .04) and OS (HR, 1.85; P = .03). In the multivariate analysis, OS maintained statistical significance (HR, 1.85; P = .04). CONCLUSIONS: The variability in TBI techniques resulted in uncertainty with reported lung doses. Lateral fields were associated with higher lung dose, and thus they should be avoided. Patients treated with lung dose <800 cGy in this study had better outcomes. This approach is currently being investigated in the Children's Oncology Group AALL1331 study. Additionally, the Imaging and Radiation Oncology Core Group is evaluating effects of TBI techniques on lung doses using a phantom.
RCT Entities:
PURPOSE: To examine the relationship between lung radiation dose and survival outcomes in children undergoing total body irradiation (TBI)-based hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia on the Children's Oncology Group trial. METHODS AND MATERIALS: TBI (1200 or 1320 cGy given twice daily in 6 or 8 fractions) was used as part of 3 HSCT preparative regimens, allowing institutional flexibility regarding TBI techniques, including lung shielding. Lung doses as reported by each participating institution were calculated for different patient setups, with and without shielding, with a variety of dose calculation techniques. The association between lung dose and transplant-related mortality, relapse-free survival, and overall survival (OS) was examined using the Cox proportional hazards regression model controlling for the following variables: TBI dose rate, TBI fields, patient position during TBI, donor type, and pre-HSCT minimal residual disease level. RESULTS: Of a total of 143 eligible patients, 127 had lung doses available for this analysis. The TBI techniques were heterogeneous. The mean lung dose was reported as 904.5 cGy (standard deviation, ±232.3). Patients treated with lateral fields were more likely to receive lung doses ≥800 cGy (P < .001). The influence of lung dose ≥800 cGy on transplant-related mortality was not significant (hazard ratio [HR], 1.78; P = .21). On univariate analysis, lung dose ≥800 cGy was associated with inferior relapse-free survival (HR, 1.76; P = .04) and OS (HR, 1.85; P = .03). In the multivariate analysis, OS maintained statistical significance (HR, 1.85; P = .04). CONCLUSIONS: The variability in TBI techniques resulted in uncertainty with reported lung doses. Lateral fields were associated with higher lung dose, and thus they should be avoided. Patients treated with lung dose <800 cGy in this study had better outcomes. This approach is currently being investigated in the Children's Oncology Group AALL1331 study. Additionally, the Imaging and Radiation Oncology Core Group is evaluating effects of TBI techniques on lung doses using a phantom.
Authors: Chris R Kelsey; Mitchell E Horwitz; Junzo P Chino; Oana Craciunescu; Beverly Steffey; Rodney J Folz; Nelson J Chao; David A Rizzieri; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-06 Impact factor: 7.038
Authors: Darren Zuro; Stefano Vagge; Sara Broggi; Stefano Agostinelli; Yutaka Takahashi; Jamison Brooks; Paulina Leszcynska; An Liu; Claudio Zucchetti; Simonetta Saldi; Chunhui Han; Mauro Cattaneo; Sebastian Giebel; Marc Andre Mahe; James F Sanchez; Parham Alaei; Chiara Anna; Kathryn Dusenbery; Antonio Pierini; Guy Storme; Cynthia Aristei; Jeffrey Y C Wong; Susanta Hui Journal: Radiother Oncol Date: 2019-08-14 Impact factor: 6.280
Authors: Bianca A W Hoeben; Jeffrey Y C Wong; Lotte S Fog; Christoph Losert; Andrea R Filippi; Søren M Bentzen; Adriana Balduzzi; Lena Specht Journal: Front Pediatr Date: 2021-12-03 Impact factor: 3.418
Authors: Darren M Zuro; Gabriel Vidal; James Nathan Cantrell; Yong Chen; Chunhui Han; Christina Henson; Salahuddin Ahmad; Susanta Hui; Imad Ali Journal: Front Oncol Date: 2022-07-28 Impact factor: 5.738
Authors: Monzr M Al Malki; Joycelynne Palmer; Ni-Chun Tsai; Sally Mokhtari; Susanta Hui; Weimin Tsai; Ibrahim Aldoss; Haris Ali; Ahmed Aribi; Thai Cao; Mathew Mei; Karamjeet S Sandhu; Tanya Siddiqi; Stephen J Forman; Ryotaro Nakamura; Guido Marcucci; Anthony Stein; Jeffrey Y C Wong; Joseph Rosenthal Journal: Blood Adv Date: 2022-07-26